Bioventix Competitors and Similar CompaniesClear all
Bioventix's competitors and similar companies include Biocept, Universal Diagnostics, Vela Diagnostics and Pacific Edge.
 Bioventix Bioventix is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drug of abuse testing. |  Biocept Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer. |  Universal Diagnostics Universal Diagnostics (UDX) is a bioinformatics, multi-omics, and in-vitro diagnostics company that develops minimally invasive and blood-based solutions for detecting cancer. |  Vela Diagnostics Vela Diagnostics is a supplier of integrated molecular solutions for the diagnosis of infectious diseases and cancer. | ||
Founding Date | Founding Date 2003 | Founding Date 1993 | Founding Date 2012 | Founding Date 2011 | Founding Date 2001 |
Type | Type Public | Type Public | Type Private | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Farnham, GB HQ | Locations San Diego, US HQ | Locations Seville, ES HQ Ljubljana, SI Madrid, ES Cambridge, US | Locations Singapore, SG HQ Hamburg, DE Suisun, US | Locations Dunedin, NZ HQ Singapore, SG |
Employees | Employees 17 | Employees 878% decrease | Employees 1271% increase | Employees 951% decrease | Employees 114 |
Valuation ($) | Valuation ($) 251.1 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) £13.1m (FY, 2025) | Revenue (est.) $25.9m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $11.5m (FY, 2026) |
Cost of goods | Cost of goods £1.1m (FY, 2025) | Cost of goods $28.4m (FY, 2022) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit £12m (FY, 2025) | Gross profit ($2.5m) (FY, 2022) | Gross profit N/A | Gross profit N/A | Gross profit $13m (FY, 2026) |
Net income | Net income £7.6m (FY, 2025) | Net income ($32.1m) (FY, 2022) | Net income N/A | Net income N/A | Net income ($35.8m) (FY, 2026) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 15.9m | Total funding raised N/A | Total funding raised $ 225k | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Biocept
HQ
San Diego, US
Employees
87↓ 8% decrease
Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer.
View companyUniversal Diagnostics
HQ
Seville, ES
Employees
127↑ 1% increase
Universal Diagnostics (UDX) is a bioinformatics, multi-omics, and in-vitro diagnostics company that develops minimally invasive and blood-based solutions for detecting cancer.
View companyVela Diagnostics
HQ
Singapore, SG
Vela Diagnostics is a supplier of integrated molecular solutions for the diagnosis of infectious diseases and cancer.
View company